Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

86 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale.
Isakoff SJ, Puhalla S, Domchek SM, Friedlander M, Kaufman B, Robson M, Telli ML, Diéras V, Han HS, Garber JE, Johnson EF, Maag D, Qin Q, Giranda VL, Shepherd SP. Isakoff SJ, et al. Among authors: puhalla s. Future Oncol. 2017 Feb;13(4):307-320. doi: 10.2217/fon-2016-0412. Epub 2016 Oct 14. Future Oncol. 2017. PMID: 27739325 Free PMC article. Clinical Trial.
Erratum to Metaplastic Breast Carcinoma: A Clinical-Pathologic Study of 97 Cases With Subset Analysis of Response to Neoadjuvant Chemotherapy [Modern Pathology 32(6) (2019) 807-816].
Han M, Salamat A, Zhu L, Zhang H, Clark BZ, Dabbs DJ, Carter GJ, Brufsky AM, Jankowitz RC, Puhalla SL, Johnson RR, Soran A, Steiman JG, McAuliffe PF, Diego EJ, Bhargava R. Han M, et al. Among authors: puhalla sl. Mod Pathol. 2023 Aug;36(8):100267. doi: 10.1016/j.modpat.2023.100267. Epub 2023 Jul 13. Mod Pathol. 2023. PMID: 37453277 No abstract available.
Long-Term Follow-Up of the Anthracyclines in Early Breast Cancer Trials (USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 [NRG Oncology]).
Geyer CE Jr, Blum JL, Yothers G, Asmar L, Flynn PJ, Robert NJ, Hopkins JO, O'Shaughnessy JA, Rastogi P, Puhalla SL, Hilton CJ, Dang CT, Gómez HL, Vukelja SJ, Lyss AP, Paul D, Brufsky AM, Colangelo LH, Swain SM, Mamounas EP, Wolmark N. Geyer CE Jr, et al. Among authors: puhalla sl. J Clin Oncol. 2024 Apr 20;42(12):1344-1349. doi: 10.1200/JCO.23.01428. Epub 2024 Feb 9. J Clin Oncol. 2024. PMID: 38335467
PARP inhibitors in breast cancer: BRCA and beyond.
Rios J, Puhalla S. Rios J, et al. Among authors: puhalla s. Oncology (Williston Park). 2011 Oct;25(11):1014-25. Oncology (Williston Park). 2011. PMID: 22106552 Free article. Review.
Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study.
Han HS, Diéras V, Robson M, Palácová M, Marcom PK, Jager A, Bondarenko I, Citrin D, Campone M, Telli ML, Domchek SM, Friedlander M, Kaufman B, Garber JE, Shparyk Y, Chmielowska E, Jakobsen EH, Kaklamani V, Gradishar W, Ratajczak CK, Nickner C, Qin Q, Qian J, Shepherd SP, Isakoff SJ, Puhalla S. Han HS, et al. Among authors: puhalla s. Ann Oncol. 2018 Jan 1;29(1):154-161. doi: 10.1093/annonc/mdx505. Ann Oncol. 2018. PMID: 29045554 Free PMC article. Clinical Trial.
Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies.
Appleman LJ, Beumer JH, Jiang Y, Lin Y, Ding F, Puhalla S, Swartz L, Owonikoko TK, Donald Harvey R, Stoller R, Petro DP, Tawbi HA, Argiris A, Strychor S, Pouquet M, Kiesel B, Chen AP, Gandara D, Belani CP, Chu E, Ramalingam SS. Appleman LJ, et al. Among authors: puhalla s. Cancer Chemother Pharmacol. 2019 Dec;84(6):1289-1301. doi: 10.1007/s00280-019-03960-w. Epub 2019 Sep 23. Cancer Chemother Pharmacol. 2019. PMID: 31549216 Free PMC article. Clinical Trial.
Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Diéras V, Han HS, Kaufman B, Wildiers H, Friedlander M, Ayoub JP, Puhalla SL, Bondarenko I, Campone M, Jakobsen EH, Jalving M, Oprean C, Palácová M, Park YH, Shparyk Y, Yañez E, Khandelwal N, Kundu MG, Dudley M, Ratajczak CK, Maag D, Arun BK. Diéras V, et al. Among authors: puhalla sl. Lancet Oncol. 2020 Oct;21(10):1269-1282. doi: 10.1016/S1470-2045(20)30447-2. Epub 2020 Aug 27. Lancet Oncol. 2020. PMID: 32861273 Clinical Trial.
Relevance of Platinum-free Interval and BRCA Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for gBRCA Advanced Breast Cancer (BROCADE3 Crossover).
Puhalla SL, Diéras V, Arun BK, Kaufman B, Wildiers H, Han HS, Ayoub JP, Stearns V, Yuan Y, Helsten T, Riley-Gillis B, Murphy E, Kundu MG, Wu M, Maag D, Ratajczak CK, Ramathal CY, Friedlander M. Puhalla SL, et al. Clin Cancer Res. 2021 Sep 15;27(18):4983-4993. doi: 10.1158/1078-0432.CCR-21-0748. Epub 2021 Jun 15. Clin Cancer Res. 2021. PMID: 34131001 Free PMC article.
Efficacy and safety of first-line veliparib and carboplatin-paclitaxel in patients with HER2- advanced germline BRCA+ breast cancer: Subgroup analysis of a randomised clinical trial.
Arun BK, Han HS, Kaufman B, Wildiers H, Friedlander M, Ayoub JP, Puhalla SL, Bell-McGuinn KM, Bach BA, Kundu MG, Ratajczak CK, Maag D, Diéras V. Arun BK, et al. Among authors: puhalla sl. Eur J Cancer. 2021 Sep;154:35-45. doi: 10.1016/j.ejca.2021.05.037. Epub 2021 Jul 6. Eur J Cancer. 2021. PMID: 34243076 Free article. Clinical Trial.
86 results